T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
iShares Core S&P 500 ETF
IVV
$910B
| $11.2M | ﹤0.01% |
16,289
+79
| +0.5% | +$53.6K |
|
1202
MGM Resorts International
MGM
$11.1B
| $11.1M | ﹤0.01% |
304,570
+2,004
| +0.7% | +$68K |
|
1203
Lincoln Electric
LECO
$15.6B
| $11.1M | ﹤0.01% |
46,360
+1,235
| +3% | +$293K |
|
|
TGB
1204
Trekor Metals
TGB
$3.2B
| $11.1M | ﹤0.01% |
+1,960,260
| New | +$9.22M |
|
1205
Timken Company
TKR
$9.03B
| $11M | ﹤0.01% |
131,038
+11,825
| +10% | +$941K |
|
1206
Restaurant Brands International
QSR
$26.1B
| $11M | ﹤0.01% |
161,222
+11,573
| +8% | +$797K |
|
1207
Powell Industries
POWL
$7.58B
| $11M | ﹤0.01% |
103,503
+1,083
| +1% | +$122K |
|
1208
Teradata
TDC
$2.49B
| $10.9M | ﹤0.01% |
359,508
-63,020
| -15% | -$1.65M |
|
1209
Erie Indemnity
ERIE
$13.5B
| $10.9M | ﹤0.01% |
38,054
+514
| +1% | +$153K |
|
|
SAIL
1210
SailPoint Inc
SAIL
$11.3B
| $10.9M | ﹤0.01% |
537,530
+5,928
| +1% | +$124K |
|
1211
Littelfuse
LFUS
$11.4B
| $10.8M | ﹤0.01% |
42,576
-1,482
| -3% | -$377K |
|
1212
Zai Lab
ZLAB
$2.86B
| $10.6M | ﹤0.01% |
602,954
-345,717
| -36% | -$8.09M |
|
1213
Franklin Resources
BEN
$17.1B
| $10.6M | ﹤0.01% |
444,481
-5,261
| -1% | -$121K |
|
1214
Ally Financial
ALLY
$13.6B
| $10.6M | ﹤0.01% |
232,973
+11,720
| +5% | +$483K |
|
1215
Maplebear
CART
$11.2B
| $10.5M | ﹤0.01% |
233,260
-175,035
| -43% | -$7.16M |
|
|
AMRZ
1216
Amrize Ltd
AMRZ
$25.6B
| $10.4M | ﹤0.01% |
192,258
+3,500
| +2% | +$179K |
|
1217
BHP
BHP
$222B
| $10.4M | ﹤0.01% |
171,734
| – | – |
|
1218
Hormel Foods
HRL
$13.4B
| $10.3M | ﹤0.01% |
435,348
-39
| -0% | -$910 |
|
|
RNAM
1219
DELISTED
Avidity Biosciences
RNAM
| $10.3M | ﹤0.01% |
142,888
-9,644,529
| -99% | -$623M |
|
1220
Omega Healthcare
OHI
$13.9B
| $10.3M | ﹤0.01% |
231,937
+18,061
| +8% | +$778K |
|
1221
Janux Therapeutics
JANX
$978M
| $10.3M | ﹤0.01% |
744,466
-521,090
| -41% | -$12.3M |
|
1222
MediWound
MDWD
$179M
| $10.2M | ﹤0.01% |
554,498
-60,005
| -10% | -$1.1M |
|
1223
Symbotic
SYM
$5.35B
| $10.2M | ﹤0.01% |
171,593
-46,121
| -21% | -$3.05M |
|
1224
Brookfield Asset Management
BAM
$87.1B
| $10.1M | ﹤0.01% |
193,092
+13,366
| +7% | +$719K |
|
1225
Zillow
Z
$7.48B
| $10.1M | ﹤0.01% |
147,655
+14,629
| +11% | +$1.06M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.